Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Giorgino

Showing results (11-20 of 241) with videos related to

Pageof 25
Sort By:
Diabetes Research and Clinical Practice|June 16, 2005
Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategiesFrancesco Giorgino, Luigi Laviola, Anna Leonardini
Diabetes Care|July 22, 2016
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?Francesco Giorgino, Philip D Home, Jaakko Tuomilehto
Diabetes, Obesity & Metabolism|April 15, 2020
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?Francesco Giorgino, Jiten Vora, Peter Fenici, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 21, 2008
Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humansLuigi Laviola, Annalisa Natalicchio, Sebastio Perrini, et al.
Archives of Physiology and Biochemistry|October 24, 2008
Biological specificity of visceral adipose tissue and therapeutic interventionSebastio Perrini, Anna Leonardini, Luigi Laviola, et al.
International Journal of Molecular Sciences|July 13, 2024
Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and ParagangliomasFrancesca Torresan, Clelia Iacobone, Francesco Giorgino, et al.
Metabolism: Clinical and Experimental|December 11, 2019
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failureFrancesco Giorgino, Irene Caruso, Julia Moellmann, et al.
Cardiovascular Diabetology|November 23, 2020
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal riskFrancesco Giorgino, Jiten Vora, Peter Fenici, et al.
Journal of Diabetes Science and Technology|July 13, 2017
Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled TrialsEdoardo Mannucci, Alessandro Antenore, Francesco Giorgino, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trialFrancesco Giorgino, Alka Shaunik, Minzhi Liu, et al.
Pageof 25

Showing results (11-20 of 241) with videos related to

Sort By:
Pageof 25
Diabetes Research and Clinical Practice|June 16, 2005
Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategiesFrancesco Giorgino, Luigi Laviola, Anna Leonardini
Diabetes Care|July 22, 2016
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?Francesco Giorgino, Philip D Home, Jaakko Tuomilehto
Diabetes, Obesity & Metabolism|April 15, 2020
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?Francesco Giorgino, Jiten Vora, Peter Fenici, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 21, 2008
Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humansLuigi Laviola, Annalisa Natalicchio, Sebastio Perrini, et al.
Archives of Physiology and Biochemistry|October 24, 2008
Biological specificity of visceral adipose tissue and therapeutic interventionSebastio Perrini, Anna Leonardini, Luigi Laviola, et al.
International Journal of Molecular Sciences|July 13, 2024
Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and ParagangliomasFrancesca Torresan, Clelia Iacobone, Francesco Giorgino, et al.
Metabolism: Clinical and Experimental|December 11, 2019
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failureFrancesco Giorgino, Irene Caruso, Julia Moellmann, et al.
Cardiovascular Diabetology|November 23, 2020
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal riskFrancesco Giorgino, Jiten Vora, Peter Fenici, et al.
Journal of Diabetes Science and Technology|July 13, 2017
Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled TrialsEdoardo Mannucci, Alessandro Antenore, Francesco Giorgino, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trialFrancesco Giorgino, Alka Shaunik, Minzhi Liu, et al.
Pageof 25